Hostname: page-component-848d4c4894-2pzkn Total loading time: 0 Render date: 2024-05-01T03:30:18.868Z Has data issue: false hasContentIssue false

Conventional neuroleptics and rehabilitation in schizophrenic patients

Published online by Cambridge University Press:  16 April 2020

L Colonna*
Affiliation:
CHS du Rouvray, Service Hospitalo-Universitaire, 4 rue Paul-Éluard, BP 45, 76301Sotteville-les-Rouen cedex, France
Get access

Summary

Nowadays, the rehabilitation of schizophrenic patients is a major issue for psychiatry. Regarding the role of conventional neuroleptics, the following points will be considered in this paper: the role of neuroleptics in the number, length and frequency of hospitalisations; the role of neuroleptics in the number, degree and length of relapses; the clinical effects of neuroleptics focusing particularly on their disinhibitory action, the most controversial and least studied of the clinical effects of these drugs; and the side effects, which have been intensively studied and particularly criticised during these last years, leading to the development of new drugs discussed in the next article. All the published data relating to the psychosocial profile of schizophrenic patients clearly demonstrate the need for further research in order to improve the familial, social and professional rehabilitation of these patients

Type
Research Article
Copyright
Copyright © Elsevier, Paris 1996

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Berner, PA propos de la méthodologie du suivi des psychoses au long cours.Guyotat, J eds. Colloque des psychoses au long cours Paris: Spécia, 1989; 113Google Scholar
Boron, JPinchard, ACollard, JClinical classification of neuroleptic with special reference to their antimanic, antiautistic and ataraxic properties. Compr Psychiatry 1972; 13: 123–31Google Scholar
Boyer, PPuech, AJLecrubier, YEtude en double insu contre placebo de l’Amisulpride (Solian ® 50) à faibles doses chez des schizophrènes purement déficitaires. Ann Psychiat 1988;3(3bis):321–5Google Scholar
Colodron, AProblèmes posés par le traitement actuel du syndrome schizophrénique. Research and clinical forums 1993;15(2):2734Google Scholar
Colonna, LL’effet stimulant des neuroleptiques. Mythe ou réalité? Encéphale 1979; 5: 239–42Google Scholar
Davis, JMDose equivalence of antipsychotic drugs. J Psychiatr Res 1974; 11: 65–910.1016/0022-3956(74)90071-5CrossRefGoogle ScholarPubMed
Davis, JMCole, JOAntipsychotic drugs.Freedman, AMKaplan, HISadock, BJ eds. Comprehensive Textbook of Psychiatry Baltimore: The Williams & Wilkins Cie Ed, USA, 1978; 1921–40Google Scholar
Davis, JAndriukaitis, SThe natural course of schizophrenia and effective maintenance drug treatment. J Clin Psycho-Pharmacol. 1986;6:2S10S10.1097/00004714-198602001-00002CrossRefGoogle ScholarPubMed
Delay, JDeniker, PMéthodes chimiothérapiques en psychiatrie Paris: Masson, 1961Google Scholar
Demangeat, M, et al. Thérapie et réadaptation. Expérience de huit années d’un hôpital de jour intersecteur à Bordeaux. Actual Psychiat. 1341983 23–6Google Scholar
Deniker, PPsychopharmacologie. Paris: Elipses, 1987Google Scholar
Deniker, PGinestet, DNeuroleptiques. Psychiatrie Paris, France:Encycl Med Chir 2-1973 37860Google Scholar
Dollfus, SPetit, MEssai d’évaluation de l’efficacité des neuroleptiques sur le devenir des schizophrénies. Encéphale 1991; 17: 247–53Google Scholar
Garrone, GLalive, JVez, ALa vie sociale des psychotiques. Actual psychiat 1979; 9(1): 2837Google Scholar
Ginestet, DClassification thérapeutique des neuroleptiques. Séminaire de Psychiatrie Biologique Paris: Fournier, 1984; 115–27Google Scholar
Ginestet, DLes neuroleptiques: développement et situation actuelle. Encéphale 1991; 17: 149–52Google Scholar
Got, RQuidu, MPrésentation du Centre de Réadaptation de Billiers. Actual Psychiat 1981;11(3):1316Google Scholar
Itil, TMSaletu, BHsu, WKiremitci, MKeskiner, AClinical and quantitative EEG changes at different dosage levels of fluphenazine treatment. Acta Psychiatr Scand 1971; 47: 440–5110.1111/j.1600-0447.1971.tb03701.xCrossRefGoogle ScholarPubMed
Jolivet, BArgumentaire sur la réhabilitation en tant que pôle social de la réadaptation. Actual Psychiat 1989;19(5):4850Google Scholar
Kendler, KSGruenberg, AMTsuang, MTOutcome of schizophrenia subtypes defined by four diagnostic systems. Arch Gen Psychiat 1984; 41: 149–5410.1001/archpsyc.1984.01790130045006CrossRefGoogle ScholarPubMed
Peraud, MCDanon-Boileau, HLab, PLe devenir de 1000 malades étudiants hospitalisés entre 1956 et 1966: enquête catamnestique. Ann Med Psychol 1975; 1: 150Google Scholar
Petit, MColonna, LCritères de choix d’un neuroleptique. Entretiens de Bichat, Thérapeutique Paris: Expansion Scientifique Française, 1978; 306–8Google Scholar
Petit, MZann, MColonna, LEtude contrôlée de l’effet désinhibiteur de faibles doses de sulpiride dans les psychoses schizophréniques déficitaires. Encéphale 1984; 10: 557–9Google Scholar
Sartorius, NJablensky, AErnber, G, et al. Course of schizophrenia in different countries: some results of a WHO. international comparative five year follow-up study. Search for the courses of schizophrenia Berlin: Springer-Verlag, 1987 10.1007/978-3-642-71765-9_10CrossRefGoogle Scholar
Singer, LKapter, TLe centre d’aide par le travail, son rôle dans le traitement des psychoses chroniques. Psychiatr Franç 1988;13(2):101–5Google Scholar
Zann, MColonna, LPetit, MLesieur, PHEtude contrôlée de l’effet désinhibiteur du sulpiride chez 18 patients hébéphrènes. Psychol Med 1986;18(4):569–70Google Scholar
Submit a response

Comments

No Comments have been published for this article.